Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED
精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

FURTHER DELAY IN DESPATCH OF THE CIRCULAR AND FURTHER EXTENSION OF THE LONG STOP DATE IN RELATION TO THE MAJOR TRANSACTION INVOLVING THE PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS

References are made to (i) the announcement of Extrawell Pharmaceutical Holdings Limited (the "**Company**") dated 2 December 2025 (the "**Announcement**") regarding to the entering into of the Fourth Amendment Deed in relation to the Proposed Fourth Amendments to the terms and conditions of the Bonds; (ii) the announcements of the Company dated 27 February 2026, 29 May 2026, 11 September 2026 (the "**Delay Announcement**") and 30 September 2026 regarding the delay in despatch of the Circular and the extension of the Long Stop Date in respect of the major transaction in relation to the Fourth Amendment Deed. Unless the context otherwise requires, terms defined in this announcement shall have the same meanings as those defined in the Announcement.

FURTHER DELAY IN DESPATCH OF THE CIRCULAR

As disclosed in the Delay Announcement, the Circular was expected to be despatched to the Shareholders on or before 15 November 2026. As (i) the trading in the shares of Starcoin on the Stock Exchange has been suspended with effect from 9:00 a.m. on Wednesday, 6 May 2026, and will remain suspended until further notice; (ii) additional time is required to fulfil all the Conditions Precedent contemplated under the Fourth Amendment Deed; and (iii) additional time is required to prepare and finalise certain information to be included in the Circular, the Company expects that the date of the despatch of the Circular will be further postponed from 15 November 2026 to a date on or before 10 February 2027.

FURTHER EXTENSION OF THE LONG STOP DATE

In view of the further delay in despatch of the Circular and the convening of the SGM, the Company has entered into an extension letter with Starcoin on 30 October 2026 (after trading hours) to further extend the Long Stop Date for fulfilment of the Conditions Precedent of the Fourth Amendment Deed from 31 October 2026 to 28 February 2027 or such other date as the Parties may agree.

Save as aforesaid, all other terms and provisions of the Fourth Amendment Deed shall remain the same and unchanged and continue in full force and effect.

WARNING NOTICE

Shareholders and potential investors should note that the Fourth Amendment Deed is conditional upon fulfillment of all the Conditions Precedent. Hence, the transactions contemplated under the Fourth Amendment Deed may or may not be materialized. Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 30 October 2026

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Guo Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Wu Xiangyun, and the independent non-executive directors are Ms. Jin Song, Dr. Zeng Li and Ms. Yang Xiaorong.

* *For identification purpose only*